Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 19, 2025 03:40 ET | Source: Teva Pharmaceutical Industries Ltd

Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®

According to the settlement agreement, the proposed biosimilar to Eylea® (aflibercept) can be marketed in the U.S., if approved by the FDA, in the fourth quarter of 2026, or earlier under certain...
December 11, 2025 03:01 ET | Source: Bio Usawa Inc

Bio Usawa Welcomes Global Health Strategist, Professor Prashant Yadav, as Chair of Its Global Access and Health Equity Advisory Board

SAN FRANCISCO and KIGALI, Rwanda, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Bio Usawa Inc., a biotechnology company dedicated to developing and delivering high-quality, affordable medicines, today announced...
November 25, 2025 08:10 ET | Source: Teva Pharmaceutical Industries Ltd

Teva receives European Commission approvals for PONLIMSI® (denosumab) Biosimilar to Prolia® and DEGEVMA® (denosumab) Biosimilar to Xgeva®

Following the positive opinions of the Committee for Medicinal Products for Human Use (CHMP), the European Commission has granted marketing authorizations for Teva’s biosimilars PONLIMSI and DEGEVMA...
November 03, 2025 09:20 ET | Source: SNS Insider pvt ltd

Cell Line Development Market to Reach USD 12.56 Billion by 2032, Driven by Rising Demand for Biologics, Gene Therapies, and Biopharmaceutical Innovation – SNS Insider

Austin, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Cell Line Development Market Size & Growth Analysis According to SNS Insider, the global Cell Line Development Market was valued at USD 5.46 billion in...
October 29, 2025 00:50 ET | Source: Bio Usawa Inc

Bio Usawa Takes Strategic Step into Europe with New Subsidiary in Frankfurt, Germany

KIGALI, Rwanda and FRANKFURT, Germany and SAN FRANCISCO, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Bio Usawa Biotechnology Ltd (Rwanda) proudly announces the establishment of its new European subsidiary,...
September 11, 2025 05:40 ET | Source: SNS Insider pvt ltd

Prescription Drugs Market to Surpass USD 2.17 Trillion by 2032, Fueled by Rising Prevalence of Chronic Diseases and Strong U.S. Market Leadership – SNS Insider

Pune, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Prescription Drugs Market Size & Growth Analysis: According to SNS Insider, the global Prescription Drugs Market (処方薬市場)was valued at 1,162.60 USD...
August 21, 2025 12:30 ET | Source: Custom Market Insights

[Latest] Global Biologics and Biosimilars Market Size/Share Worth USD 1,320.19 Billion by 2034 at a 10.42% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

Austin, TX, USA, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Biologics and Biosimilars Market Size, Trends and Insights By Product Type...
July 23, 2025 10:00 ET | Source: AscellaHealth, LLC

AscellaHealth Service and Infrastructure Enhancements Support Specialty Drug Manufacturers to Protect Market Share Across Brand, Biosimilar and Generic Launches

AscellaHealth Service and Infrastructure Enhancements Support Specialty Drug Manufacturers
July 01, 2025 07:15 ET | Source: Bio Usawa Inc

Bio Usawa Biotechnology and Bioeq AG Partner to Create Widespread Access to Vision-Saving Medicine Across Sub-Saharan Africa

Bio Usawa Biotechnology Ltd. and Bioeq AG today announced a partnership to bring a life-changing biosimilar of ranibizumab to Sub-Saharan Africa.
June 27, 2025 10:23 ET | Source: BCC Research LLC

Biosimilars Market on the Rise: Expected 19.4% CAGR Over Next Five Years

Boston, June 27, 2025 (GLOBE NEWSWIRE) -- According to the latest study from BCC Research, “Biosimilars: Global Markets” is expected to grow from $28.5 billion in 2024 to $69.2 billion by the end of...